Thursday tips round-up: Ocado, Hikma Pharmaceuticals
13th Mar 2014 10:09
Ocado's share price is riding on a lot of assumptions. So much so that in a rational market its shares should not be where they are and they should not be headed any higher. At the moment it is trading at a price-to-earnings multiple of 200 and even if it meets forecasts that would still leave share
Read moreFTSE 250 movers: Hikma Pharmaceuticals jumps after strong 2013
12th Mar 2014 14:43
Powerful revenue growth from its generic drugs and solid growth elsewhere helped Hikma Pharmaceutical post impressive results for 2013. Group revenue increased 23% to $1,365m and a 30% strengthening of operating margins from improvements in the Generics and Injectables businesses helped group prof
Read moreWednesday broker round-up UPDATE
12th Mar 2014 09:03
Ashtead Group: Citi raises target price from 850p to 1075p keeping a buy recommendation. Barratt Developments: Goldman Sachs reduces target price from 527p to 502p and downgrades to neutral. British Land: Jefferies downgrades to hold with a target price of 707p. Brooks Macdonald Group: Canaccord
Read moreLondon pre-open: Potential second Chinese bond default to hit FTSE
12th Mar 2014 07:45
- FTSE to open around 60 points lower - Reports of potential second bond default in China - Data out on US Crude Oil Inventories and EU Industrial Production The City is set to start the day firmly in reverse on the back of reports of another bond default in China and a negative finish in the US la
Read moreHikma Pharma ups dividend as generics generate generous cash - UPDATE
12th Mar 2014 07:07
- Revenue and EPS up 23 and 111 per cent - Final and special dividend of 13c and 4c - Growth expected in 2014 despite pullback in generics Powerful revenue growth from its generic drugs and solid growth elsewhere helped Hikma Pharmaceutical post impressive results for 2013. Group revenue increas
Read moreTuesday broker round-up UPDATE
11th Mar 2014 09:03
Aviva: RBC Capital takes target price from 400p to 550p upgrading to neutral. Nomura increases target price from 489p to 625p and reiterates a buy recommendation. Balfour Beatty: Citi raises target price from 220p to 310p maintaining a neutral rating. Goldman Sachs reduces target price from 335p to
Read moreFTSE 250 movers: Kazakhmys extends rise on currency valuation change
14th Feb 2014 14:48
Copper miner Kazakhmys surged today, extending gains made earlier this week after the Kazakh government devalued its local currency which investors hope will lead to lower costs for the firm. Shares of Essar Energy are rocketing after the company announced that all main units have resumed operation
Read moreFriday broker round-up UPDATE
14th Feb 2014 10:26
Assura Group: Liberum Capital shifts target price from 44p to 44.40p and retains a buy recommendation. Barclays: Credit Suisse lowers target price from 270p to 260p and keeps a neutral rating. Bellway: Panmure Gordon raises target price from 1520p to 1639p and maintains a buy recommendation. UBS i
Read moreHikma Pharmaceuticals to deliver higher than expected FY revenue
14th Feb 2014 08:04
Hikma Pharmaceuticals on Friday reported a strong performance by its Injectables business ahead of the release of its 2013 results next month, which it said would now show a higher-than-expected revenue increase. The group said revenue for the 12-month period would now be around 23% above the prior
Read moreWednesday broker round-up UPDATE
27th Nov 2013 09:14
Aviva: Nomura moves target price from 474p to 489p retaining a buy recommendation. Bellway: Numis upgrades to buy with a target price of 1690p. Breedon Aggregates: Jefferies starts with a target price of 42p and a buy recommendation. Britvic: UBS ups target price from 575p to 600p and keeps a neu
Read moreHikma signs syringe supply deal with Unilife Corp
20th Nov 2013 07:08
Pharmaceuticals group Hikma has signed a 15-year commercial supply deal with US firm Unilife Corporation for the use of its Unifill prefilled syringes. Pennsylvania-based Unilife will supply Hikma with customised prefillable syringes to be used with a range of the FTSE 250 group's generic injectabl
Read moreCarillion Finance Director lowers holding
8th Nov 2013 16:03
Carillion's Group Finance Director, Richard Adam, on Thursday sold, on behalf of his wife, 40,000 shares. Each of these was sold for 309.04p, for a total trade value of £123,616. Adam's stake now stands at 118,238 shares. The disposal was made a week after the support services company announced
Read moreFriday broker round-up UPDATE
8th Nov 2013 09:21
Abcam: Canaccord Genuity moves target price from 396p to 386p and keeps a sell recommendation. N+1 Singer shifts target price from 450p to 445p downgrading to sell. Aberdeen Asset Management: Jefferies lowers target price from 440p to 430p and reiterates a hold recommendation. Anglo American: Gold
Read moreHikma Pharmaceuticals expects annual revenue growth
8th Nov 2013 07:45
Hikma Pharmaceuticals said it is maintaining its guidance for 2013 for 20 per cent revenue growth on the back of a strong performance across all its divisions. The group's global Injectables business has delivered robust results, particularly in the US, where growth is being driven by demand acros
Read moreHikma signs joint venture with MIDROC to enter Ethiopian market
18th Sep 2013 07:28
Hikma Pharmaceuticals has signed a joint venture agreement with MIDROC Pharmaceuticals to enter the Ethiopian medicine market. The joint venture, HikmaCure, will establish an Ethiopian operating company, build a local manufacturing facility and begin marketing and distributing pharmaceutical produ
Read more